FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366209251> ?p ?o ?g. }

• W4366209251 abstract "Background Echinacea purpurea has clinical antiviral activity against respiratory viruses and modulates immune functions. In this study, we compared higher doses of new Echinacea formulations with conventional formulations at lower, preventive doses for therapy of respiratory tract infections (RTIs). Methods In this randomized, blinded, controlled trial, healthy adults ( n = 409) were randomized between November 2018 and January 2019 to one of four Echinacea formulations, which were taken in case of an RTI for up to 10 days. New formulations A (lozenges) and B (spray) delivered an increased dose of 16,800 mg/d Echinacea extract during days 1–3 and 2,240–3,360 mg/d afterward; as controls, conventional formulations C (tablets) and D (drops) delivered a lower daily dose of 2,400 mg, usually taken for prevention. The primary endpoint was time to clinical remission of first RTI episodes based on the Kaplan–Meier analysis of patient-reported, investigator-confirmed, respiratory symptoms assessed for up to 10 days. In a sensitivity analysis, the mean time to remission beyond day 10 was calculated by extrapolating the treatment effects observed on days 7 to 10. Results A total of 246 participants (median age 32 years, 78% female participants) were treated for at least one RTI. Recovery by day 10 (complete absence of symptoms) was achieved in 56 and 44% of patients with the new and conventional formulations, respectively, showing a median time to recovery of 10 and 11 days, respectively ( p = 0.10 in intention-to-treat analysis, p = 0.07 in per-protocol analysis). In the extrapolated sensitivity analysis, new formulations resulted in a significantly shorter mean time to remission (9.6 vs. 11.0 days, p &lt; 0.001). Among those with an identified respiratory virus, viral clearance until day 10 based on real-time PCR from nasopharyngeal swabs was more frequent with new formulations (70 vs. 53%, p = 0.046). Tolerability and safety (adverse events: 12 vs. 6%, p = 0.19) were good and similar between formulations. There was one severe adverse event with a potential hypersensitivity reaction in a recipient of the novel spray formulation. Conclusion In adults with acute RTI, new Echinacea formulations with higher doses resulted in faster viral clearance than conventional formulations in prophylactic dosages. The trend for faster clinical recovery was not significant by day 10 but became so upon extrapolation. A dose increase during acute respiratory symptoms might improve the clinical benefits of orally administered Echinacea formulations. Trial registration The study was registered in the Swiss National Clinical Trials Portal (SNCTP000003069) and on ClinicalTrials.gov (NTC03812900; URL https://clinicaltrials.gov/ct2/show/NCT03812900?cond=echinacea&amp;draw=3&amp;rank=14 )." @default.
• W4366209251 created "2023-04-19" @default.
• W4366209251 creator A5002998900 @default.
• W4366209251 creator A5012060154 @default.
• W4366209251 creator A5018730778 @default.
• W4366209251 creator A5021356974 @default.
• W4366209251 creator A5028829460 @default.
• W4366209251 creator A5045966169 @default.
• W4366209251 creator A5050136338 @default.
• W4366209251 creator A5050143427 @default.
• W4366209251 creator A5071503350 @default.
• W4366209251 creator A5072889836 @default.
• W4366209251 creator A5075698019 @default.
• W4366209251 creator A5075719411 @default.
• W4366209251 creator A5077178350 @default.
• W4366209251 creator A5080523158 @default.
• W4366209251 date "2023-04-17" @default.
• W4366209251 modified "2023-10-14" @default.
• W4366209251 title "Novel Echinacea formulations for the treatment of acute respiratory tract infections in adults—A randomized blinded controlled trial" @default.
• W4366209251 cites W1833340009 @default.
• W4366209251 cites W1984218383 @default.
• W4366209251 cites W1986231627 @default.
• W4366209251 cites W1996289202 @default.
• W4366209251 cites W2011162259 @default.
• W4366209251 cites W2055973923 @default.
• W4366209251 cites W2060500581 @default.
• W4366209251 cites W2079387436 @default.
• W4366209251 cites W2091613552 @default.
• W4366209251 cites W2104104394 @default.
• W4366209251 cites W2106393500 @default.
• W4366209251 cites W2109794175 @default.
• W4366209251 cites W2114506463 @default.
• W4366209251 cites W2127062009 @default.
• W4366209251 cites W2154047132 @default.
• W4366209251 cites W2163713022 @default.
• W4366209251 cites W2171609823 @default.
• W4366209251 cites W2172050318 @default.
• W4366209251 cites W2172204730 @default.
• W4366209251 cites W2196342997 @default.
• W4366209251 cites W2300593182 @default.
• W4366209251 cites W2412931168 @default.
• W4366209251 cites W2802831895 @default.
• W4366209251 cites W2924802935 @default.
• W4366209251 cites W3013994177 @default.
• W4366209251 cites W3085069628 @default.
• W4366209251 cites W3112440110 @default.
• W4366209251 cites W3112642823 @default.
• W4366209251 cites W3150792096 @default.
• W4366209251 cites W4220832497 @default.
• W4366209251 cites W4226323479 @default.
• W4366209251 cites W4230647413 @default.
• W4366209251 cites W68134370 @default.
• W4366209251 doi "https://doi.org/10.3389/fmed.2023.948787" @default.
• W4366209251 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37138742" @default.
• W4366209251 hasPublicationYear "2023" @default.
• W4366209251 type Work @default.
• W4366209251 citedByCount "0" @default.
• W4366209251 crossrefType "journal-article" @default.
• W4366209251 hasAuthorship W4366209251A5002998900 @default.
• W4366209251 hasAuthorship W4366209251A5012060154 @default.
• W4366209251 hasAuthorship W4366209251A5018730778 @default.
• W4366209251 hasAuthorship W4366209251A5021356974 @default.
• W4366209251 hasAuthorship W4366209251A5028829460 @default.
• W4366209251 hasAuthorship W4366209251A5045966169 @default.
• W4366209251 hasAuthorship W4366209251A5050136338 @default.
• W4366209251 hasAuthorship W4366209251A5050143427 @default.
• W4366209251 hasAuthorship W4366209251A5071503350 @default.
• W4366209251 hasAuthorship W4366209251A5072889836 @default.
• W4366209251 hasAuthorship W4366209251A5075698019 @default.
• W4366209251 hasAuthorship W4366209251A5075719411 @default.
• W4366209251 hasAuthorship W4366209251A5077178350 @default.
• W4366209251 hasAuthorship W4366209251A5080523158 @default.
• W4366209251 hasBestOaLocation W43662092511 @default.
• W4366209251 hasConcept C126322002 @default.
• W4366209251 hasConcept C168563851 @default.
• W4366209251 hasConcept C203014093 @default.
• W4366209251 hasConcept C203092338 @default.
• W4366209251 hasConcept C2776012195 @default.
• W4366209251 hasConcept C2778136109 @default.
• W4366209251 hasConcept C2778225391 @default.
• W4366209251 hasConcept C534529494 @default.
• W4366209251 hasConcept C535046627 @default.
• W4366209251 hasConcept C556039675 @default.
• W4366209251 hasConcept C71924100 @default.
• W4366209251 hasConcept C90924648 @default.
• W4366209251 hasConceptScore W4366209251C126322002 @default.
• W4366209251 hasConceptScore W4366209251C168563851 @default.
• W4366209251 hasConceptScore W4366209251C203014093 @default.
• W4366209251 hasConceptScore W4366209251C203092338 @default.
• W4366209251 hasConceptScore W4366209251C2776012195 @default.
• W4366209251 hasConceptScore W4366209251C2778136109 @default.
• W4366209251 hasConceptScore W4366209251C2778225391 @default.
• W4366209251 hasConceptScore W4366209251C534529494 @default.
• W4366209251 hasConceptScore W4366209251C535046627 @default.
• W4366209251 hasConceptScore W4366209251C556039675 @default.
• W4366209251 hasConceptScore W4366209251C71924100 @default.
• W4366209251 hasConceptScore W4366209251C90924648 @default.
• W4366209251 hasLocation W43662092511 @default.
• W4366209251 hasLocation W43662092512 @default.
• W4366209251 hasLocation W43662092513 @default.

• next